View Older Stories View More Recent Stories

Jul 31, 2020 05:15AM Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate
Jul 31, 2020 05:15AM Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate
Jul 27, 2020 05:16PM Pfizer (PFE), BioNTech (BNTX) Choose Lead mRNA Vaccine Candidate Against COVID-19, Commence Pivotal Phase 2/3 Global Study
Jul 27, 2020 05:16PM Pfizer (PFE) and BioNTech (BNTX) Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
Jul 27, 2020 05:15PM Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
Jul 27, 2020 05:15PM Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
Jul 27, 2020 05:15PM Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study
Jul 22, 2020 10:51AM Transgene Reports Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers
Jul 22, 2020 07:11AM Pfizer (PFE) and BioNTech (BNTX) Announce Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 22, 2020 07:10AM Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 22, 2020 07:10AM Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 22, 2020 07:10AM Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 20, 2020 08:46AM Pfizer (PFE), BioNTech SE (BNTX) Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study
Jul 20, 2020 08:45AM Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
Jul 20, 2020 08:45AM Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
Jul 20, 2020 08:45AM Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
Jul 20, 2020 06:00AM Pfizer (PFE), BioNTech SE (BNTX) Report Agreement with the U.K. for 30M Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 20, 2020 01:00AM Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 20, 2020 01:00AM Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2
Jul 20, 2020 01:00AM Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 13, 2020 06:46AM Pfizer (PFE), BioNTech SE (BNTX) Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against COVID-19
Jul 13, 2020 06:45AM Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Jul 13, 2020 06:45AM Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Jul 13, 2020 06:45AM Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Jul 9, 2020 09:03AM   Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance
Jul 6, 2020 04:00AM Mission Raises $15m and Expands its Relationship with Pfizer
Jul 1, 2020 09:01AM Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 1, 2020 09:01AM Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jul 1, 2020 09:00AM Pfizer (PFE) and BioNTech (BNTX) Confirms Early Positive Data from an Ongoing Phase 1/2 COVID-19 Trial
Jul 1, 2020 08:59AM Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Jun 30, 2020 06:45PM FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Jun 25, 2020 12:14PM Pfizer Declares Third-Quarter 2020 Dividend
Jun 24, 2020 07:00AM Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa
Jun 22, 2020 08:01AM Pfizer (PFE) Reports Initiation of Four Phase 3 Clinical Trials for Investigational Vaccines
Jun 22, 2020 08:00AM Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines
Jun 18, 2020 09:05AM Pfizer (PFE), Sangamo (SGMO) Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelp
Jun 18, 2020 09:00AM Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (S
Jun 18, 2020 09:00AM Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (S
Jun 16, 2020 01:23PM Merck (MRK), Pfizer (PFE) Report SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes & Atherosclerotic Cardiovascular Disease
Jun 16, 2020 01:15PM Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Jun 16, 2020 10:00AM Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
Jun 12, 2020 10:00AM Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th
Jun 11, 2020 08:05AM Pfizer (PFE) Announces FDA Approves its Oncology Supportive Care Biosimilar, NYVEPRIA
Jun 11, 2020 08:00AM FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)
Jun 10, 2020 06:46AM Pfizer (PFE) Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe AD
Jun 10, 2020 06:45AM Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis
Jun 3, 2020 04:32PM Pfizer (PFE) announces JAMA Dermatology has published complete results from second Phase 3 monotherapy pivotal study of abrocitinib
Jun 3, 2020 04:30PM Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology
Jun 2, 2020 10:00AM Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Jun 2, 2020 06:00AM Pfizer Establishes New Program to Support Continued Biotechnology Innovation
View More Recent Stories View Older Stories